Career Center AES Connect

Abstracts

Describing the Population of Patients With Prolonged Seizures: US Subgroup Results From a Global Real-World Point-In-Time Study

Abstract number : 1.305
Submission category : 4. Clinical Epilepsy / 4C. Clinical Treatments
Year : 2025
Submission ID : 764
Source : www.aesnet.org
Presentation date : 12/6/2025 12:00:00 AM
Published date :

Authors :
Presenting Author: Eugen Trinka, MD, MSc, FRCP – Christian Doppler University Hospital, Member of the European Reference Network EpiCARE, and Centre for Cognitive Neuroscience, Paracelsus Medical University, Salzburg, Austria

Matthew Walker, MA, MBBChir, PhD, FRCP – UCL Queen Square Institute of Neurology, Department of Clinical & Experimental Epilepsy, UCL, London, United Kingdom
Reeta Kälviäinen, MD, PhD – Department of Neurology, School of Medicine, University of Eastern Finland and Kuopio Epilepsy Center, Kuopio, Finland
Sheryl Haut, MD – Montefiore Medical Center, Albert Einstein Center, Albert Einstein College of Medicine, Bronx, NY, United States
John Stern, MD – Department of Neurology, University of California, Los Angeles, CA, United States
Lawrence Hirsch, MD – Yale University School of Medicine
Alexander Gillespie, BSc – Adelphi Real World, Bollington, United Kingdom
Laura LeBrocq, BSc – Adelphi Real World, Bollington, United Kingdom
Eliza Smith, MSci – Adelphi Real World, Bollington, United Kingdom
Cédric Laloyaux, PhD – UCB, Brussels, Belgium
Olaf Radunz, MSc – UCB, Brussels, Belgium
J Claire Wilson, PhD – UCB, Slough, United Kingdom

Rationale: People with epilepsy (PwE) can experience prolonged seizures (PS), which may progress to status epilepticus (SE; seizure(s) lasting ≥ 5 minutes). However, the definition of PS and patient population have not been well characterized.

Methods: Data for the US subpopulation were drawn from RWE0807 Adelphi’s PS Disease Specific Programme™ (DSP), a real-world, point-in-time study conducted in France, Germany, Italy, Spain, UK, US, Japan, and China, from March 2023–February 2024. Neurologists/epileptologists/internal medicine specialists completed record forms for PwE aged ≥12 years who had received a stable regimen of antiseizure medication and experienced ≥ 1 PS (lasting ≥ 2 minutes and/or longer than their normal seizures) in the prior 12 months. Physicians recorded each patient’s demographics, seizure characteristics, treatment including rescue medication (RM), condition burden, and healthcare resource utilization (HCRU). PwE self‑reported seizure worry using a 0-10 scale (10=“worry all the time”). Data are reported for PwE who had experienced ≥ 1 PS, for both their PS and non-PS (lasting < 2 minutes).

Results: 55 neurologists and 7 epileptologists completed records for 545 PwE experiencing PS. Median [Q1-Q3] patient age was 39 [29-50] years, 55% male, and 23% required assistance from someone responsible for their daily needs. 39% of PwE with PS had ever experienced SE, and 24% experienced seizure clusters (SCs). During the prior 12 months, 27% of PwE had PS that progressed to SE; early ictal events were similarly experienced by PwE for both PS and non-PS events; both SCs and injuries were more commonly experienced by PwE in relation to their PS vs non‑PS events (Figure 1). During the prior 12 months, a higher proportion of PwE with PS required HCRU for their PS than their non-PS (Figure 2). 70% of PwE with PS were currently prescribed RM, and oral benzodiazepines (including buccal midazolam) were the most commonly prescribed RM (oral benzodiazepines: 37% [n=141/379]; intranasal midazolam: 32% [n=122/379]; intranasal diazepam: 27% [n=102/379]; rectal diazepam: 7% [n=25/379]). Seizure action plans (SAPs) for PS were in place for 67% of PwE with PS; when physicians were asked if their patient followed their SAP for their PS, 63% (n=215/341) responded “always”. During the prior 3 months, PwE with PS reported being more worried about when their next PS would occur than when their next non‑PS would occur (self-reported seizure worry: PS median [Q1-Q3]: 7.0 [5.0-8.0], n=33; non-PS: 5.0 [3.0-7.3], n=38).

Conclusions: PwE experiencing PS are reported to encounter progression to status epilepticus and/or seizure clusters, leading to emergency care, and hospital, emergency room, and intensive care unit admissions. Approximately two-thirds of PwE with PS have a seizure action plan for PS. PS have a subsequent impact on seizure worry among some PwE with PS. To prevent seizure progression to more severe states, better options for treating PS are needed.

Funding:

UCB-sponsored



Clinical Epilepsy